tovorafenib
Ipsen Secures Ex-US Rights to Day One’s Pediatric Cancer Medication with $111M Upfront Investment
Ipsen, Day One, Pediatric Cancer, Tovorafenib, Ex-US Rights, $111M Upfront Investment
Actionable Insights Powered by AI
Ipsen, Day One, Pediatric Cancer, Tovorafenib, Ex-US Rights, $111M Upfront Investment